Life Sciences

The Right Chemistry

Life sciences and medical devices companies face a unique set of operational and financial challenges, from conducting clinical trials to bringing products to market to expanding operations—all within a complex regulatory environment. How do successful businesses overcome these hurdles? It starts with seeking out the right mix of industry-specific accounting, tax, and consulting expertise.

Our integrated service approach provides our clients with functional expertise, industry knowledge, and specialized services to help them overcome financial challenges and take advantage of valuable opportunities.

Who We Serve

Our Life Sciences & Medical Devices Practice serves organizations of all sizes—from large multinational companies and publicly traded middle-market corporations to private firms and start-ups. Our clients specialize in many areas, including:

  • Biotechnology
  • Diagnostics
  • Medical devices
  • Pharmaceuticals
  • Digital health

Life Sciences Guides

Insights


Alert
President Trump signs federal funding bill that suspends the medical device excise tax until January 2020.

Alert
Tax reform will have significant 2017 income tax implications for technology, life sciences, and communications and media companies.

Webcast
Many states changed their laws this year to generate more tax revenue from out-of-state companies, creating potential tax implications for technology, communications and media, and life sciences companies. Companies should be diligent about identifying changes in their income tax, sales and use tax, or other tax exposure.

Article
Our 2017 Q4 update covers potential tax reform changes, state and local tax strategies, applying for the R&D payroll tax credit, and more.

Article
Our Q3 update covers accounting methods and other current issues for companies in tech, clean tech, life sciences, and communications and media.

Webcast
The new revenue rules are long, complex, and involve judgment to apply, and waiting until just before the effective date to consider how the new rules may alter your company’s financial statements is far too late.

National Practice Leader

Industry Professionals